tiprankstipranks
Trending News
More News >
Sonnet Biotherapeutics Holdings, Inc. (SONN)
:SONN
US Market
Advertisement

Sonnet BioTherapeutics Holdings (SONN) AI Stock Analysis

Compare
614 Followers

Top Page

SONN

Sonnet BioTherapeutics Holdings

(NASDAQ:SONN)

Rating:49Neutral
Price Target:
$3.50
▼(-3.05% Downside)
Sonnet BioTherapeutics Holdings' overall stock score is primarily impacted by its poor financial performance, with significant challenges in revenue generation and profitability. While recent corporate events provide some optimism, the company's valuation remains unattractive due to negative earnings. Technical analysis suggests mixed signals, with no strong momentum in either direction.

Sonnet BioTherapeutics Holdings (SONN) vs. SPDR S&P 500 ETF (SPY)

Sonnet BioTherapeutics Holdings Business Overview & Revenue Model

Company DescriptionSonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
How the Company Makes MoneySonnet BioTherapeutics generates revenue through a combination of product development agreements, partnerships, and potential licensing agreements for its therapeutic candidates. The company may also receive milestone payments and royalties from collaborations with pharmaceutical firms that seek to utilize its innovative therapeutic technologies. Additionally, government grants and funding may contribute to its financial resources, especially for early-stage development projects. Significant partnerships with larger biotech or pharmaceutical companies can enhance its revenue streams by providing access to additional resources, expertise, and commercialization capabilities.

Sonnet BioTherapeutics Holdings Financial Statement Overview

Summary
Sonnet BioTherapeutics Holdings faces significant financial challenges, characterized by declining revenues, negative profitability, and high leverage. The company's financial health is concerning, with negative equity and cash flow issues. These factors suggest a need for strategic restructuring or capital infusion to stabilize operations and improve financial performance.
Income Statement
20
Very Negative
Sonnet BioTherapeutics Holdings has struggled with consistent revenue generation, showing a significant decline from 2019 to 2024. The company has experienced negative net income and EBIT margins, indicating ongoing operational challenges and lack of profitability. The revenue growth rate is volatile, reflecting instability in revenue streams.
Balance Sheet
15
Very Negative
The balance sheet reveals high leverage with negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, highlighting a precarious financial position. The company's assets have significantly decreased over the years, further stressing its financial instability.
Cash Flow
25
Negative
Cash flow analysis shows persistent negative free cash flow, indicating cash burn without sufficient inflow. Operating cash flow is consistently negative, and the free cash flow to net income ratio is unfavorable. Despite some financing inflows, the company struggles to generate positive cash flow from operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.00M18.63K147.81K349.94K483.63K0.00
Gross Profit-951.93K18.63K147.81K-21.09M483.63K-58.31K
EBITDA-13.99M-11.77M-18.72M-29.58M-24.99M-24.24M
Net Income-13.56M-7.44M-18.83M-29.77M-25.01M-24.27M
Balance Sheet
Total Assets2.06M2.77M5.43M5.83M28.99M7.99M
Cash, Cash Equivalents and Short-Term Investments321.30K149.46K2.27M3.05M27.62M7.35M
Total Debt68.84K130.86K203.91K255.99K125.88K353.25K
Total Liabilities5.10M3.26M5.66M8.37M6.73M4.97M
Stockholders Equity-3.05M-485.74K-225.98K-2.54M22.26M3.02M
Cash Flow
Free Cash Flow-10.31M-8.61M-21.79M-28.58M-22.56M-15.69M
Operating Cash Flow-10.31M-8.61M-21.34M-27.69M-22.55M-15.61M
Investing Cash Flow-12.00K-12.00K-443.25K-896.48K-3.62K-76.18K
Financing Cash Flow7.09M6.49M21.01M4.01M42.83M23.01M

Sonnet BioTherapeutics Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.61
Price Trends
50DMA
3.65
Negative
100DMA
2.46
Positive
200DMA
2.15
Positive
Market Momentum
MACD
-0.10
Negative
RSI
50.78
Neutral
STOCH
46.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONN, the sentiment is Positive. The current price of 3.61 is above the 20-day moving average (MA) of 3.25, below the 50-day MA of 3.65, and above the 200-day MA of 2.15, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 50.78 is Neutral, neither overbought nor oversold. The STOCH value of 46.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SONN.

Sonnet BioTherapeutics Holdings Risk Analysis

Sonnet BioTherapeutics Holdings disclosed 82 risk factors in its most recent earnings report. Sonnet BioTherapeutics Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sonnet BioTherapeutics Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.83B-0.15-40.10%2.29%21.46%-2.01%
49
Neutral
$24.38M-714.96%1689.52%66.05%
44
Neutral
$17.01M-134.50%68.67%85.44%
40
Underperform
$8.09M-67.73%-2.06%64.86%
38
Underperform
$16.90M-276.72%2.00%-87.50%92.82%
37
Underperform
$8.33M354.78%91.46%
36
Underperform
$26.92M-56.12%95.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SONN
Sonnet BioTherapeutics Holdings
3.61
-2.21
-37.97%
CYCC
Cyclacel Pharmaceuticals
7.49
-258.91
-97.19%
TENX
Tenax Therapeutics
5.90
2.03
52.45%
VYNE
VYNE Therapeutics
0.32
-1.48
-82.22%
LGVN
Longeveron
0.82
-1.30
-61.32%
CLDI
Calidi Biotherapeutics
1.70
-12.10
-87.68%

Sonnet BioTherapeutics Holdings Corporate Events

Executive/Board Changes
Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao
Neutral
Aug 1, 2025

On July 31, 2025, Sonnet BioTherapeutics Holdings, Inc. entered into an employment agreement with Raghu Rao, the interim Chief Executive Officer, outlining his compensation and potential bonuses. The agreement includes a base salary of $400,000, eligibility for a bonus based on strategic transactions, and discretionary bonuses from the board. Additionally, the board approved a $100,000 discretionary bonus for Mr. Rao on the same date.

Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Sonnet BioTherapeutics Regains Nasdaq Compliance After Fundraising
Positive
Jul 25, 2025

On May 30, 2025, Sonnet BioTherapeutics Holdings received a deficiency notice from Nasdaq for not meeting the $2.5 million minimum stockholders’ equity requirement. However, by July 18, 2025, the company reported raising sufficient funds through private placement and warrant exercises, ensuring compliance with Nasdaq’s equity rule. On July 23, 2025, Nasdaq confirmed the company’s compliance but will continue to monitor its financial status, with potential delisting if future requirements are not met.

Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Sonnet BioTherapeutics Secures Funding to Meet Nasdaq Requirements
Positive
Jul 18, 2025

On May 30, 2025, Sonnet BioTherapeutics Holdings received a deficiency notice from Nasdaq for not meeting the $2.5 million minimum stockholders’ equity requirement. By July 15, 2025, the company secured approximately $5.5 million from a private placement offering and an additional $10.5 million from warrant exercises, potentially bringing it back into compliance, pending Nasdaq’s confirmation.

M&A TransactionsBusiness Operations and Strategy
Sonnet BioTherapeutics Announces Merger with Rorschach I LLC
Positive
Jul 14, 2025

Sonnet BioTherapeutics announced a business combination with Rorschach I LLC to form Hyperliquid Strategies Inc (HSI), a public cryptocurrency treasury company. The transaction, valued at $888 million, will see HSI holding a significant reserve of HYPE tokens, the native token of the Hyperliquid blockchain. This move is expected to transform Sonnet’s business by integrating a cryptocurrency treasury strategy while continuing its focus on existing biotech assets. The merger, subject to approval by Sonnet stockholders, is anticipated to close in the second half of 2025, with HSI listed on Nasdaq under a new ticker symbol.

Private Placements and Financing
Sonnet BioTherapeutics Completes $2 Million Convertible Notes Sale
Neutral
Jul 2, 2025

On June 30, 2025, Sonnet BioTherapeutics Holdings, Inc. completed a sale of $2.0 million in convertible notes to accredited investors, along with warrants to purchase 865,052 shares of common stock. The convertible notes, maturing on June 30, 2026, can be converted into up to 1,730,104 shares of common stock at a conversion price of $1.156. If a subsequent issuance of at least $5.0 million occurs within 90 days, the notes will automatically convert into the same securities issued in that offering.

Delistings and Listing ChangesRegulatory Filings and Compliance
Sonnet BioTherapeutics Faces Nasdaq Non-Compliance Notice
Negative
Jun 2, 2025

On May 30, 2025, Sonnet BioTherapeutics Holdings received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company reported stockholders’ equity of $662,262, significantly below the $2.5 million requirement. Sonnet has until July 14, 2025, to submit a compliance plan, with potential extensions up to 180 days. Failure to regain compliance could lead to delisting, impacting liquidity, trading volume, and the company’s ability to raise capital, thereby affecting its business operations and investor confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025